Earth Science Tech, Inc. (ETST) Subsidiary Readies
Post# of 333
(Total Views: 270)
Posted On: 06/27/2018 6:23:10 PM
Earth Science Tech, Inc. (ETST) Subsidiary Readies International Marketing, Sales Launch of MSN-2 Home Medical Testing Kit for Women
- ETST is in the process of trademarking and finalizing packaging for a medical device designed to detect sexually transmitted infections
- The biotech company is focused on developing medical devices for the pharmaceutical and nutraceutical fields and marketing its high-grade line of hemp cannabidiol (CBD)
- ETST is bringing to market non-invasive medical devices and vaccines for women; in vitro testing on the impact of its CBD formula on breast cancer cells to begin in summer of 2019
Earth Science Tech, Inc. (OTC: ETST), through its Earth Science Pharmaceutical subsidiary, is finalizing plans to launch global marketing and sales of its MSN-2 home testing medical kit for the detection of sexually transmitted infections (STI) in women. ETST plans to market it in such far-flung countries as Vietnam and Morocco (http://nnw.fm/Afx5b).
ETST, a biotech company based in Doral, Florida, has repositioned its line of full spectrum CBD. As it conducts R&D for non-invasive medical devices, it is also focused on manufacturing, marketing and distributing its own cannabinoid products, including capsules and oils, to the nutraceutical and pharmaceutical markets.
The company’s MSN-2 medical device is in its final stage prior to the launch of large scale marketing. ETST is working with Acceleration, Design et Innovation Inc. Final packaging is being designed to appeal worldwide to its target audience of women. The device is developed to detect chlamydia and other STIs. It is a home kit that collects human cells which are then laboratory tested ( http://nnw.fm/Dos5T).
In a news release, Dr. Michel Aube, CEO and chief science officer of ETST, stated, “We will create a strong demand for this medical device by showing the world its powerful capacity to diminish the prevalence of chlamydia and other sexually transmitted infections.” He noted that ETST is in the process of obtaining trademark protection for its logo and name.
In addition, funded by a grant from Quebec, Canada, ETST is now prototyping three CBD patent formulas. In vitro testing will begin on the first batch of formulas in the summer of 2019 to show the superior antioxidant properties and anti-proliferative effects on breast cancer cells. The branding of these products is in the planning stage.
ETST holds several wholly-owned subsidiaries. Cannabis Therapeutics is an emerging biotechnology company. KannaBidioiD manufactures and distributes in the recreational sector. Earth Science Foundation, Inc. is becoming a non-profit and accepts grants and donations to conduct additional studies. Earth Science Pharmaceutical develops medical diagnostic tools and vaccines. It also has subsidiary Canno Inno Laboratories Inc., a strategic Montreal, Canada-based company formed to provide ETST with access to government grants.
For more information, visit the company’s website at www.EarthScienceTech.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- ETST is in the process of trademarking and finalizing packaging for a medical device designed to detect sexually transmitted infections
- The biotech company is focused on developing medical devices for the pharmaceutical and nutraceutical fields and marketing its high-grade line of hemp cannabidiol (CBD)
- ETST is bringing to market non-invasive medical devices and vaccines for women; in vitro testing on the impact of its CBD formula on breast cancer cells to begin in summer of 2019
Earth Science Tech, Inc. (OTC: ETST), through its Earth Science Pharmaceutical subsidiary, is finalizing plans to launch global marketing and sales of its MSN-2 home testing medical kit for the detection of sexually transmitted infections (STI) in women. ETST plans to market it in such far-flung countries as Vietnam and Morocco (http://nnw.fm/Afx5b).
ETST, a biotech company based in Doral, Florida, has repositioned its line of full spectrum CBD. As it conducts R&D for non-invasive medical devices, it is also focused on manufacturing, marketing and distributing its own cannabinoid products, including capsules and oils, to the nutraceutical and pharmaceutical markets.
The company’s MSN-2 medical device is in its final stage prior to the launch of large scale marketing. ETST is working with Acceleration, Design et Innovation Inc. Final packaging is being designed to appeal worldwide to its target audience of women. The device is developed to detect chlamydia and other STIs. It is a home kit that collects human cells which are then laboratory tested ( http://nnw.fm/Dos5T).
In a news release, Dr. Michel Aube, CEO and chief science officer of ETST, stated, “We will create a strong demand for this medical device by showing the world its powerful capacity to diminish the prevalence of chlamydia and other sexually transmitted infections.” He noted that ETST is in the process of obtaining trademark protection for its logo and name.
In addition, funded by a grant from Quebec, Canada, ETST is now prototyping three CBD patent formulas. In vitro testing will begin on the first batch of formulas in the summer of 2019 to show the superior antioxidant properties and anti-proliferative effects on breast cancer cells. The branding of these products is in the planning stage.
ETST holds several wholly-owned subsidiaries. Cannabis Therapeutics is an emerging biotechnology company. KannaBidioiD manufactures and distributes in the recreational sector. Earth Science Foundation, Inc. is becoming a non-profit and accepts grants and donations to conduct additional studies. Earth Science Pharmaceutical develops medical diagnostic tools and vaccines. It also has subsidiary Canno Inno Laboratories Inc., a strategic Montreal, Canada-based company formed to provide ETST with access to government grants.
For more information, visit the company’s website at www.EarthScienceTech.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)